- Margin shortfalls have been disappointing, but AngioDynamics' key growth drivers are still intact and the Med Tech portfolio is growing nicely.
- AngioVac remains the likeliest growth driver, though Auryon could surprise and NanoKnife could be a significant data-driven opportunity in a few years.
- AngioDynamics looks undervalued, but with single-digit total revenue growth and weak operating profitability for the foreseeable future, there is a risk it falls between the cracks for a while longer.
For further details see:
AngioDynamics - Progress Despite Margin And Pandemic Challenges